Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes

This study has been completed.
Information provided by (Responsible Party):
Alcon Research Identifier:
First received: December 19, 2007
Last updated: November 29, 2012
Last verified: November 2012
The purpose of this study is to determine if a topical otic formulation is safe and effective in treating middle ear infections in patients with ear tubes.

Condition Intervention Phase
Acute Otitis Media
Drug: Moxidex otic solution
Drug: Moxifloxacin otic solution
Device: Tympanostomy tubes
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT)

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Time to cessation of otorrhea as recorded by the parent or guardian via a patient diary [ Time Frame: From baseline ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical cure rate [ Time Frame: From baseline ] [ Designated as safety issue: No ]
  • Microbiological outcome [ Time Frame: From baseline ] [ Designated as safety issue: No ]
  • Treatment failures [ Time Frame: From baseline ] [ Designated as safety issue: No ]

Enrollment: 776
Study Start Date: January 2006
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Moxidex
Moxidex otic solution
Drug: Moxidex otic solution
4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Device: Tympanostomy tubes
Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Active Comparator: Moxifloxacin
Moxifloxacin otic solution
Drug: Moxifloxacin otic solution
4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Device: Tympanostomy tubes
Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children


Ages Eligible for Study:   6 Months to 12 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 6 months to 12 years old
  • Ear tubes in one or both ears
  • Ear drainage visible by the parent / guardian
  • Ear drainage less than 21 days
  • Ear tube may not be silver oxide, silver salt, t-type tube or long-shafted tube
  • Patient may not have non-tube otorrhea
  • Patient may not have had otic surgery other than tube placement in the last year
  • Patient may not be a menarchal female
  • Diabetic patients are not eligible
  • Patient may not have any disease or condition that would negatively affect the conduct of the study
  • Patient may not require any other systemic antimicrobial therapy during the study.
  • Patient must meet certain medication washouts to be eligible
  • Analgesic use (other than acetaminophen) is not allowed
  • Patient may not be pre-disposed to neurosensory hearing loss
  • Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

  • Age
  • Other protocol-defined exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00579189

Sponsors and Collaborators
Alcon Research
Study Director: Contact Alcon Call Center 1-888-451-3937
  More Information

Responsible Party: Alcon Research Identifier: NCT00579189     History of Changes
Other Study ID Numbers: C-05-36 
Study First Received: December 19, 2007
Last Updated: November 29, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Alcon Research:
ear tubes
ear drainage
ear infection
ear drops

Additional relevant MeSH terms:
Otitis Media
Ear Diseases
Otorhinolaryngologic Diseases
Norgestimate, ethinyl estradiol drug combination
Pharmaceutical Solutions
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Combined
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on April 27, 2016